Board to approve September quarter and half-year results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹148.95

prior close

₹146.05

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.2%-3.3% vs sector

On the reaction day the stock moved 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

+1.3

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5pendingpending-0.2-3.3

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on 12 November 2026 to approve unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026. The trading window has been closed since 30 September and will reopen 48 hours after the results are announced. The filing contains no financial results.

Likely market impact

This is only a meeting notice. No financial performance is disclosed, so the effect on the share price cannot yet be assessed.

By the numbers

The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.